Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4174794 in Participants With Obesity or Overweight
NCT07654972Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2026
- Primary completion
- Apr 2029
- Countries
- 2
01
Overview
Phase 1, randomised trial of LY4174794 in obesity (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered Related to Study Drug at 33 weeks. Started Jun 2026; status: recruiting.
02
Drugs
LY4174794
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07654972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07654972.